NasdaqGS:CABABiotechs
Can Cabaletta Bio’s (CABA) Shift To Automated CAR T Manufacturing Redefine Its Scalability Edge?
Cellares recently announced that Cabaletta Bio’s investigational CAR T therapy rese-cel received FDA clearance of an IND amendment to use Cellares’ fully automated Cell Shuttle and Cell Q platforms for clinical manufacturing and quality control testing, with initial patient dosing now expected in the first half of 2026.
This marks the first time Cellares’ platforms are supporting an active clinical program and aligns with Cabaletta’s aim to scale rese-cel for autoimmune diseases, where...